Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model

Annals of Surgery

Volumn 255, Issue 2, 2012, Pages 319-325

  Bhattacharya, Syamal D ^b   Mi, Zhiyong ^c   Kim, Victoria M ^a   Guo, Hongtao ^b   Talbot, Lindsay J ^a   Kuo, Paul C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA SMOOTH MUSCLE ACTIN; APTAMER; MESSENGER RNA; OSTEOPONTIN; RNA; RNA APTAMER; TENASCIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL ASSAY; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT;

ADULT; ANIMALS; APTAMERS, NUCLEOTIDE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OSTEOPONTIN; REAL-TIME POLYMERASE CHAIN REACTION; SELEX APTAMER TECHNIQUE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855846614     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31823e3a1c     Document Type: Article

References (21)

1. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005.
2. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103-118.
3. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416-423. (Pubitemid 36460075)
4. Mi Z, Bhattacharya SD, Kim VM, et al. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011;32:477-487.
5. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
6. Zhao J, Dong L, Lu B, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008;135:956-968.
7. Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008;48:1834-1842.
8. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 2007;14:283-291. (Pubitemid 46231922)
9. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006;5:2957-2962. (Pubitemid 46092036)
10. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
11. Mi Z, Guo H, Russell MB, et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther. 2009;17:153-161.
12. Medico E, Gentile A, Lo CC, et al. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res. 2001;61:5861-5868. (Pubitemid 32769106)
13. Greten TF, Korangy F, Manns MP, et al. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009;100:19-23.
14. Tuerk C, MacDougal S, Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA. 1992;89:6988-6992.
15. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:2051-2059. (Pubitemid 44337631)
16. Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis. 2007;39:167-172. (Pubitemid 46117934)
17. Nagai T, Arao T, Furuta K, et al. Sorafenib inhibits the hepatocyte growth factor-mediated epithelialmesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther. 2011;10:169-177.
18. van Zijl F, Zulehner G, Petz M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5:1169-1179.
19. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415-428. (Pubitemid 46809165)
20. Saika S, Shirai K, Yamanaka O, et al. Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium. Lab Invest. 2007;87:130-138.
21. Goparaju CM, Pass HI, Blasberg JD, et al. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol. 2010;5:1516-1523.